

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 May 2025 (01.05.2025)



(10) International Publication Number
WO 2025/087862 A1

(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 31/00 (2006.01)
A61K 9/20 (2006.01) A61K 31/4178 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2024/079722

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(22) International Filing Date:

21 October 2024 (21.10.2024)

Published:

— with international search report (Art. 21(3))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23206367.7 27 October 2023 (27.10.2023) EP

(71) Applicant: ADAMED PHARMA S.A. [PL/PL]; Pienków,
ul. Mariana Adamkiewicza 6, PL 05-152 Czosnów (PL).

(72) Inventors: KUZNIEWSKA, Magdalena; ul. Zerom-
skiego 1/598, 01-887 Warszawa (PL). NIEMCZYK,
Katarzyna; ul. Grottgera 2, 32-600 Oswiecim (PL). KIRY-
LUK, Anna; ul. M. Skłodowskiej-Curie 39/27, 05-800
Pruszków (PL). WENCLAW-WALESIAK, Marta; ul.
Hektarowa 2B/5, 02-989 Warszawa (PL).

(74) Agent: SITKOWSKA, Jadwiga; Al. Komisji Edukacji
Narodowej 83/106, 02-777 Warszawa (PL).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: PHARMACEUTICAL COMPOSITION OF FURAZIDIN FOR VAGINAL ADMINISTRATION

(57) Abstract: A pharmaceutical composition of furazidin in the form of a vaginal mucoadhesive tablet, said tablet comprising or consisting of: a) a granulate containing furazidin, a pharmaceutically acceptable polymeric mucoadhesive binder, and intragranular pharmaceutically acceptable excipients, said excipients comprising or consisting of one or more intragranular fillers and an intragranular disintegrant; and b) extragranular pharmaceutically acceptable excipients, said excipients comprising or consisting of one or more extragranular fillers, an extragranular disintegrant, and a lubricant, and wherein the tablet comprises from 1 to 15% by weight of furazidin with respect to the weight of the tablet.



WO 2025/087862 A1